1naresh
Array ( [urn:ac.highwire.org:guest:identity] => Array ( [runtime-id] => urn:ac.highwire.org:guest:identity [type] => guest [service-id] => ajnr-ac.highwire.org [access-type] => Controlled [privilege] => Array ( [urn:ac.highwire.org:guest:privilege] => Array ( [runtime-id] => urn:ac.highwire.org:guest:privilege [type] => privilege-set [privilege-set] => GUEST ) ) [credentials] => Array ( [method] => guest ) ) ) 1nareshArray ( [urn:ac.highwire.org:guest:identity] => Array ( [runtime-id] => urn:ac.highwire.org:guest:identity [type] => guest [service-id] => ajnr-ac.highwire.org [access-type] => Controlled [privilege] => Array ( [urn:ac.highwire.org:guest:privilege] => Array ( [runtime-id] => urn:ac.highwire.org:guest:privilege [type] => privilege-set [privilege-set] => GUEST ) ) [credentials] => Array ( [method] => guest ) ) )Characteristics of subjects*
Characteristics Overall Donepezil Placebo No. 13 6 7 Age (yr) 68 (6.9) 64.7 (6.0) 70.9 (6.7) Education (yr)† 16.2 (2.3) 17.5 (2.1) 15.1 (2.0) Scores Pre Post Pre Post MMSE‡ 28.3 (1.7) 28.3 (1.9) 29.8 (0.4) 28.3 (1.7) 28 (2.5) ADAS-Cog§ 25.0 (5.4) 23.3 (3.5) 20.6 (5.5) 26.5 (6.5) 22.8 (6.5) NYU Delayed Recall 6.7 (3.0) 7.33 (1.0) 8.0 (2.8) 6.14 (4.1) 6.7 (2.8) fMRI task (% correct) 79.1 (11.8) 77.1 (16.4) 78.0 (10) 79.1 (8.9) 86.3 (13.5)
Note:—NYU indicates New York University; MMSE, Mini-Mental State Examination; ADAS-Cog, Alzheimer Disease Assessment Scale-Cognitive Subscale.
* All table cells list the mean and standard deviation.
† Education refers to period of formal schooling as reported by the patient.
‡ Trend (P = .09) for Treatment Group × Time interaction.
§ Significant (P < .05) main effect of time across both treatment groups.